These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37970366)

  • 1. The modulation of local and systemic anti-tumor immune response induced by methotrexate nanoconjugate in murine MC38 colon carcinoma and B16 F0 melanoma tumor models.
    Szczygieł A; Węgierek-Ciura K; Mierzejewska J; Wróblewska A; Rossowska J; Anger-Góra N; Szermer-Olearnik B; Świtalska M; Goszczyński TM; Pajtasz-Piasecka E
    Am J Cancer Res; 2023; 13(10):4623-4643. PubMed ID: 37970366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined therapy with methotrexate nanoconjugate and dendritic cells with downregulated IL-10R expression modulates the tumor microenvironment and enhances the systemic anti-tumor immune response in MC38 murine colon carcinoma.
    Szczygieł A; Węgierek-Ciura K; Wróblewska A; Mierzejewska J; Rossowska J; Szermer-Olearnik B; Świtalska M; Anger-Góra N; Goszczyński TM; Pajtasz-Piasecka E
    Front Immunol; 2023; 14():1155377. PubMed ID: 37033926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of MC38 colon cancer growth by multicomponent chemoimmunotherapy with anti-IL-10R antibodies, HES-MTX nanoconjugate, depends on application of IL-12, IL-15 or IL-18 secreting dendritic cell vaccines.
    Węgierek-Ciura K; Mierzejewska J; Szczygieł A; Rossowska J; Wróblewska A; Świtalska M; Goszczyński TM; Szermer-Olearnik B; Pajtasz-Piasecka E
    Front Immunol; 2023; 14():1212606. PubMed ID: 37545526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulatory potential of anticancer therapy composed of methotrexate nanoconjugate and dendritic cell‑based vaccines in murine colon carcinoma.
    Szczygieł A; Anger-Góra N; Węgierek-Ciura K; Mierzejewska J; Rossowska J; Goszczyński TM; Świtalska M; Pajtasz-Piasecka E
    Oncol Rep; 2021 Mar; 45(3):945-962. PubMed ID: 33432365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1.
    D'Alterio C; Buoncervello M; Ieranò C; Napolitano M; Portella L; Rea G; Barbieri A; Luciano A; Scognamiglio G; Tatangelo F; Anniciello AM; Monaco M; Cavalcanti E; Maiolino P; Romagnoli G; Arra C; Botti G; Gabriele L; Scala S
    J Exp Clin Cancer Res; 2019 Oct; 38(1):432. PubMed ID: 31661001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. IV. Therapy of murine melanoma B16 by human serum albumin-methotrexate derivative.
    Bostík J; Bures L; Spundová M
    Neoplasma; 1988; 35(3):343-9. PubMed ID: 3405342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyethyl starch as an effective methotrexate carrier in anticancer therapy.
    Goszczyński TM; Filip-Psurska B; Kempińska K; Wietrzyk J; Boratyński J
    Pharmacol Res Perspect; 2014 Jun; 2(3):e00047. PubMed ID: 25505592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The beneficial effects of l-carnitine and infliximab in methotrexate-induced hepatotoxicity: Emphasis on Notch1/Hes-1 signaling.
    Radwan SM; Abdel-Latif GA; Abbas SS; Elmongy NF; Wasfey EF
    Arch Pharm (Weinheim); 2023 Nov; 356(11):e2300312. PubMed ID: 37625018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fullerenol-Based Intracellular Delivery of Methotrexate: A Water-Soluble Nanoconjugate for Enhanced Cytotoxicity and Improved Pharmacokinetics.
    Bahuguna S; Kumar M; Sharma G; Kumar R; Singh B; Raza K
    AAPS PharmSciTech; 2018 Apr; 19(3):1084-1092. PubMed ID: 29159749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Markedly improved efficacy of edatrexate compared to methotrexate in a high-dose regimen with leucovorin rescue against metastatic murine solid tumors.
    Sirotnak FM; Otter GM; Schmid FA
    Cancer Res; 1993 Feb; 53(3):587-91. PubMed ID: 8425192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer.
    Lobo ED; Balthasar JP
    J Pharm Sci; 2005 Sep; 94(9):1957-64. PubMed ID: 16052545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Study of the Immune Microenvironment in Heterotopic Tumor Models.
    Kienzl M; Maitz K; Sarsembayeva A; Valadez-Cosmes P; Gruden E; Ristic D; Herceg K; Kargl J; Schicho R
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diselenide-crosslinked nanogels laden with gold nanoparticles and methotrexate for immunomodulation-enhanced chemotherapy and computed tomography imaging of tumors.
    Jia B; Gao Y; Ouyang Z; Shen S; Shen M; Shi X
    J Mater Chem B; 2023 May; 11(21):4808-4818. PubMed ID: 37212531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The protective effect of hesperidin on methotrexate-induced intestinal epithelial damage in rats: an experimental study.
    Acipayam C; Bayram I; Daglioglu K; Doran F; Yilmaz S; Sezgin G; Totan Ateş B; Ozkan A; Tanyeli A
    Med Princ Pract; 2014; 23(1):45-52. PubMed ID: 24247210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methotrexate-loaded folic acid of solid-phase synthesis conjugated gold nanoparticles targeted treatment for rheumatoid arthritis.
    Li X; Wang H; Zou X; Su H; Li C
    Eur J Pharm Sci; 2022 Mar; 170():106101. PubMed ID: 34936935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of PD-1 Checkpoint Blockade and Botulinum Toxin Type A1 Improves Antitumor Responses in Mouse Tumor Models of Melanoma and Colon Carcinoma.
    Kwak S; Lee JY; Kim MJ; Lee HJ; Lee DK; Kang J; Kang WH; Son WC; Cruz DJM
    Immunol Invest; 2023 Nov; 52(6):749-766. PubMed ID: 37403798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyethylene glycol conjugates of methotrexate varying in their molecular weight from MW 750 to MW 40000: synthesis, characterization, and structure-activity relationships in vitro and in vivo.
    Riebeseel K; Biedermann E; Löser R; Breiter N; Hanselmann R; Mülhaupt R; Unger C; Kratz F
    Bioconjug Chem; 2002; 13(4):773-85. PubMed ID: 12121133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
    Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
    Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate.
    Smith GK; Banks S; Blumenkopf TA; Cory M; Humphreys J; Laethem RM; Miller J; Moxham CP; Mullin R; Ray PH; Walton LM; Wolfe LA
    J Biol Chem; 1997 Jun; 272(25):15804-16. PubMed ID: 9188478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reprogramming the murine colon cancer microenvironment using lentivectors encoding shRNA against IL-10 as a component of a potent DC-based chemoimmunotherapy.
    Rossowska J; Anger N; Szczygieł A; Mierzejewska J; Pajtasz-Piasecka E
    J Exp Clin Cancer Res; 2018 Jun; 37(1):126. PubMed ID: 29954431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.